Plus Therapeutics and SpectronRx have partnered for the production of Rhenium (186Re) Obisbemeda, a radiotherapy for the treatment of central nervous system (CNS) cancers.
Plus Therapeutics is a US-based clinical-stage pharmaceutical company that develops targeted radiotherapeutics for central nervous system (CNS) cancers.
SpectronRx is a radiopharmaceutical company focused on developing and manufacturing medical isotopes for cancer diagnosis and therapy.
The two companies have signed a Manufacturing Services Agreement (MSA).
Under the terms of the agreement, SpectronRx will leverage its advanced manufacturing facilities to produce Rhenium (186Re) Obisbemeda for clinical and commercial supply.
The partnership aims to enhance the supply chain redundancy for Plus Therapeutics and address the demands of late-stage clinical trials and future commercial needs.
Plus Therapeutics president and CEO Marc Hedrick said: “In 2025, we intend to begin late-stage clinical trials and are actively preparing for commercial-level product demand.
“Therefore, now is the time to expand our supply chain and partner with leading radiopharmaceutical manufacturers such as SpectronRx that can deliver for us and our patients.
“We believe that SpectronRx’s capabilities will significantly reinforce our existing manufacturing partnerships and position us well for the long term.”
Currently, SpectronRx has more than 170,000ft2 of radiopharmaceutical contract development and manufacturing (rCDMO) space and 150 employees across five locations.
The company works together with more than 31 pharmaceutical companies in 29 countries to provide life-saving nuclear medicines, including those radiolabelled with 186Re.
Rhenium (186Re) Obisbemeda is a radiotherapy specifically designed to deliver direct targeted high-dose radiation in CNS tumours in a safe, effective, and convenient manner.
It can reduce off-target risks and improve outcomes for CNS cancer patients, compared to currently approved therapies, with a more targeted and potent radiation dose.
Also, Rhenium-186 is suitable for CNS therapeutic applications based on its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging.
SpectronRx president Anwer Rizvi said: “We are proud to align with Plus Therapeutics, leveraging our expertise in nuclear medicine manufacturing to support the advancement of Rhenium (186Re) Obisbemeda and increase patient access to this important therapy.
“This collaboration underscores our dedication to advancing nuclear medicine and providing patients with high-quality, life-saving radiotherapies. We look forward to supporting Plus Therapeutics’ mission to address the unmet needs of CNS cancer patients.”
